[go: up one dir, main page]

DK1576182T4 - Produktkvalitetsforbedring ved fremgangsmåde med dyrkning af pattedyreceller til proteinfremstilling - Google Patents

Produktkvalitetsforbedring ved fremgangsmåde med dyrkning af pattedyreceller til proteinfremstilling Download PDF

Info

Publication number
DK1576182T4
DK1576182T4 DK03808535.3T DK03808535T DK1576182T4 DK 1576182 T4 DK1576182 T4 DK 1576182T4 DK 03808535 T DK03808535 T DK 03808535T DK 1576182 T4 DK1576182 T4 DK 1576182T4
Authority
DK
Denmark
Prior art keywords
galactose
culture
sialylation
methods
sustain
Prior art date
Application number
DK03808535.3T
Other languages
English (en)
Other versions
DK1576182T3 (da
Inventor
Bernhard M Schilling
Scott Gangloff
Dharti Kothari
Kirk Leister
Linda Matlock
Stephen G Zegarelli
Jonathan O Basch
Sivakesava Sakhamuri
Steven S Lee
Christoph E Joosten
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32682324&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1576182(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of DK1576182T3 publication Critical patent/DK1576182T3/da
Publication of DK1576182T4 publication Critical patent/DK1576182T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK03808535.3T 2002-12-23 2003-12-18 Produktkvalitetsforbedring ved fremgangsmåde med dyrkning af pattedyreceller til proteinfremstilling DK1576182T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43605002P 2002-12-23 2002-12-23
PCT/US2003/040939 WO2004058944A2 (en) 2002-12-23 2003-12-18 Product quality enhancement in mammalian cell culture processes for protein production

Publications (2)

Publication Number Publication Date
DK1576182T3 DK1576182T3 (da) 2011-02-21
DK1576182T4 true DK1576182T4 (da) 2020-04-20

Family

ID=32682324

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03808535.3T DK1576182T4 (da) 2002-12-23 2003-12-18 Produktkvalitetsforbedring ved fremgangsmåde med dyrkning af pattedyreceller til proteinfremstilling

Country Status (21)

Country Link
US (2) US7332303B2 (da)
EP (1) EP1576182B2 (da)
JP (1) JP4496086B2 (da)
KR (1) KR101088223B1 (da)
CN (1) CN100402660C (da)
AT (1) ATE488600T1 (da)
AU (1) AU2003303394B2 (da)
BR (1) BR0316882A (da)
CA (1) CA2508925C (da)
CO (1) CO5590971A2 (da)
CY (1) CY1111358T1 (da)
DE (1) DE60335024D1 (da)
DK (1) DK1576182T4 (da)
ES (1) ES2354610T5 (da)
IL (1) IL168873A (da)
MX (1) MXPA05006522A (da)
PL (1) PL377603A1 (da)
PT (1) PT1576182E (da)
SI (1) SI1576182T2 (da)
TW (1) TWI328614B (da)
WO (1) WO2004058944A2 (da)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US20030219863A1 (en) * 1997-01-31 2003-11-27 Bristol-Myers Squibb Company Soluble CTLA4 mutant molecules and uses thereof
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
ATE390931T1 (de) 2001-05-23 2008-04-15 Bristol Myers Squibb Co Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4- mutationsmolekülen
JP4541157B2 (ja) 2002-12-23 2010-09-08 ブリストル−マイヤーズ スクイブ カンパニー タンパク質を製造するための哺乳類細胞培養法
ES2354610T5 (es) * 2002-12-23 2020-09-14 Bristol Myers Squibb Co Mejora de la calidad del producto en procedimientos de cultivo de células de mamífero para la producción de proteína
EP1623023B1 (en) * 2003-05-09 2008-11-12 Crucell Holland B.V. Cultures of e1-immortalized cells and processes for culturing the same to increase product yields therefrom
US7754209B2 (en) * 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
JP2007501243A (ja) 2003-08-04 2007-01-25 ブリストル−マイヤーズ　スクイブ　カンパニー 可溶性ｃｔｌａ４分子を用いる心臓血管疾患の治療方法
US7815765B2 (en) * 2004-04-01 2010-10-19 Swei Mu Wang Method for forming laminated synthetic leather
WO2006108035A1 (en) * 2005-04-06 2006-10-12 Bristol-Myers Squibb Company Methods for treating immune disorders associated with graft transplantation with soluble ctla4 mutant molecules
SI1912675T1 (sl) * 2005-07-25 2014-07-31 Emergent Product Development Seattle, Llc zmanjšanje števila celic B z uporabo molekul, ki se specifično vežejo na CD37 in CD20
US8470318B2 (en) 2005-11-07 2013-06-25 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
JP5096369B2 (ja) * 2005-12-20 2012-12-12 ブリストル−マイヤーズ スクイブ カンパニー 組成物および組成物の製造方法
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
CN101584858A (zh) 2005-12-20 2009-11-25 布里斯托尔-迈尔斯斯奎布公司 稳定蛋白质制剂
AU2007235413B2 (en) 2006-04-05 2012-08-02 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
EP2418223A3 (en) * 2006-06-12 2013-01-16 Emergent Product Development Seattle, LLC Single-chain multivalent binding proteins with effector function
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
CA2842964A1 (en) 2006-09-13 2008-03-20 Abbvie Inc. Cell culture improvements
AU2007317755A1 (en) * 2006-10-27 2008-05-15 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US9012180B2 (en) 2007-03-02 2015-04-21 Wyeth Llc Use of copper and glutamate in cell culture for production of polypeptides
EP2612867A1 (en) * 2007-11-01 2013-07-10 Perseid Therapeutics LLC Immunosuppressive polypeptides and nucleic acids
SG189772A1 (en) * 2008-04-11 2013-05-31 Trubion Pharmaceuticals Inc Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
AU2009240637A1 (en) 2008-04-22 2009-10-29 The Rockefeller University Methods of identifying anti-inflammatory compounds
US7915222B2 (en) * 2008-05-05 2011-03-29 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
AU2009307737B2 (en) 2008-10-20 2015-07-23 Abbvie Inc. Viral inactivation during purification of antibodies
NZ592095A (en) 2008-10-20 2013-01-25 Abbott Lab Isolation and purification of il-12 and tnf-alpha antibodies using protein a affinity chromatography
US9540426B2 (en) * 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
US20110262965A1 (en) * 2010-04-23 2011-10-27 Life Technologies Corporation Cell culture medium comprising small peptides
LT3330370T (lt) 2010-04-26 2021-06-10 Novartis Ag Cho ląstelių auginimo būdas
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
CN103717729B (zh) 2011-07-08 2017-11-21 动量制药公司 细胞培养方法
WO2013114245A1 (en) 2012-01-30 2013-08-08 Dr. Reddy's Laboratories Limited Process of modulating man5 and/or afucosylation content of glycoprotein composition
US20150017687A1 (en) * 2012-01-30 2015-01-15 Dr. Reddy's Laboratories Limited Method for obtaining a glycoprotein composition
WO2013114165A1 (en) * 2012-01-30 2013-08-08 Dr Reddy's Laboratories Limited Process of obtaining glycoprotein composition with increased afucosylation content
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
JP6473079B2 (ja) 2012-05-02 2019-02-20 ライフ テクノロジーズ コーポレーション 高密度増殖およびトランスフェクション培地並びに発現増強物質の固有の組み合わせを用いる、哺乳類細胞における高収率一過性発現
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
LT2867251T (lt) 2012-06-29 2019-11-25 Bristol Myers Squibb Co Glikoproteinų agregacijos sumažinimo būdai
US9664671B2 (en) 2012-07-24 2017-05-30 Nissan Chemical Industries, Ltd. Culture medium composition and method of culturing cell or tissue using thereof
US10017805B2 (en) 2012-08-23 2018-07-10 Nissan Chemical Industries, Ltd. Enhancing ingredients for protein production from various cells
JP6218285B2 (ja) * 2012-08-23 2017-10-25 日産化学工業株式会社 タンパク質産生促進剤
EP2890782A1 (en) 2012-09-02 2015-07-08 AbbVie Inc. Methods to control protein heterogeneity
US9512214B2 (en) * 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
EP2906683B1 (en) 2012-10-15 2017-05-31 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
US20140106405A1 (en) * 2012-10-15 2014-04-17 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
HK1207960A1 (en) 2013-03-12 2016-02-19 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US8956830B2 (en) 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
TWI771890B (zh) 2013-03-14 2022-07-21 美商安美基公司 用於增加重組蛋白質之甘露糖含量之方法
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
WO2014151878A2 (en) * 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
WO2014151230A2 (en) 2013-03-15 2014-09-25 Bristol-Myers Squibb Company Method of treating granulomatosis with polyangiitis
WO2014170866A2 (en) * 2013-04-18 2014-10-23 Dr. Reddy's Laboratories Limited Process of obtaining glycoprotein composition with increased galactosylation content
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
TWI642782B (zh) * 2013-10-23 2018-12-01 健臻公司 重組醣蛋白及其用途
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
EA202092845A1 (ru) 2014-01-30 2021-06-30 Кохерус Байосайенсис, Инк. Перфузионная среда
EP3134109A1 (en) 2014-04-25 2017-03-01 Bristol-Myers Squibb Company Use of ctla4 compound for achieving drug-free remission in subjects with early ra
SG11201609980TA (en) 2014-06-18 2016-12-29 Medimmune Llc Cell culture methods and media comprising n-acetylcysteine
ES2719876T3 (es) 2014-10-15 2019-07-16 Alexion Pharma Inc Métodos para replicar un cultivo celular de producción de eculizumab a gran escala
EP3072957B1 (en) 2015-03-23 2019-07-10 Lonza Ltd Methods for controlling protein glycosylation
PT3283508T (pt) 2015-04-17 2021-06-21 Alpine Immune Sciences Inc Proteínas imuno modulatórias com afinidades afináveis
US20170016043A1 (en) * 2015-07-13 2017-01-19 Life Technologies Corporation System and method for improved transient protein expression in cho cells
UA126278C2 (uk) 2015-09-21 2022-09-14 Аптево Рісьорч Енд Девелопмент Ллс Поліпептиди, які зв'язують cd3
WO2017083224A1 (en) * 2015-11-09 2017-05-18 Bristol-Myers Squibb Company Methods to manipulate quality attributes of polypeptides produced in cho cells
WO2018098375A1 (en) 2016-11-22 2018-05-31 Klotho Therapeutics, Inc. Novel recombinant klotho proteins and compositions and methods involving the same
EP3464608A4 (en) * 2016-06-02 2020-01-29 Klotho Therapeutics, Inc. THERAPEUTIC RECOMBINANT KLOTHO PROTEINS, COMPOSITIONS AND METHODS THEREFOR
CA3198255A1 (en) 2017-10-10 2019-04-18 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
WO2019136179A1 (en) 2018-01-03 2019-07-11 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
IL321253A (en) 2018-05-01 2025-08-01 Amgen Inc Antibodies with a modulated glycan profile
CN111321188B (zh) * 2018-12-17 2024-10-29 嘉和生物药业有限公司 一种抗体糖型改造的配方、细胞培养方法以及在工业化生产中的应用
KR20230152810A (ko) 2019-12-06 2023-11-03 리제너론 파아마슈티컬스, 인크. 항-vegf 단백질 조성물 및 이를 생산하는 방법
CN113025648B (zh) * 2019-12-09 2023-06-02 广东菲鹏制药股份有限公司 Expi293细胞瞬时表达目标蛋白的方法及其应用
CN111676184B (zh) * 2020-05-15 2021-01-29 上海多宁生物科技有限公司 一种由补料培养基共混的基础培养基及其制备方法和应用
US20230323422A1 (en) * 2020-08-14 2023-10-12 Bristol-Myers Squibb Company Method of making protein
CN116391043A (zh) * 2020-08-14 2023-07-04 百时美施贵宝公司 蛋白质的制造方法
US20240084355A1 (en) * 2021-02-01 2024-03-14 Dr. Reddy’S Laboratories Limited Cell culture methods
JP7589759B2 (ja) 2021-02-08 2024-11-26 株式会社島津製作所 推定装置
JP2025538819A (ja) * 2022-12-12 2025-11-28 ジェネンテック， インコーポレイテッド ポリペプチドシアル酸含有量の最適化
WO2025038362A1 (en) 2023-08-11 2025-02-20 Merck Sharp & Dohme Llc Monovalent interleukin 12 (il-12) heterodimeric fc proteins

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4357422A (en) * 1980-08-14 1982-11-02 Massachusetts Institute Of Technology Method of enhancing interferon production
FR2543158B1 (fr) * 1983-03-24 1985-11-15 Inst Nat Sante Rech Med Milieu de culture de cellules animales sans serum, sans hormones et sans facteurs de croissance et procedes de culture primaire et d'obtention de lignees cellulaires utilisant ce milieu
US5132223A (en) * 1983-11-10 1992-07-21 Thomas Jefferson University Process and medium for cloning and long-term serial cultivation of adult human endothelial cells
US4994387A (en) * 1983-11-10 1991-02-19 The Wistar Institute Process and medium for cloning and long-term serial cultivation of human endothelial cells
US5112749A (en) * 1987-10-02 1992-05-12 Praxis Biologics, Inc. Vaccines for the malaria circumsporozoite protein
DE3801236A1 (de) * 1988-01-18 1989-07-27 Boehringer Mannheim Gmbh Pentosansulfat-medium
US6352694B1 (en) * 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
IL92382A (en) 1988-11-23 1994-12-29 Univ Michigan Use of a ligand specific for CD28 in the manufacture of medicament
US5858358A (en) * 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6685941B1 (en) * 1988-11-23 2004-02-03 The Regents Of The University Of Michigan Methods of treating autoimmune disease via CTLA-4Ig
US6534055B1 (en) * 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5580756A (en) * 1990-03-26 1996-12-03 Bristol-Myers Squibb Co. B7Ig fusion protein
US7070776B1 (en) * 1990-03-26 2006-07-04 Bristol-Myers Squibb Company Methods for blocking binding of CD28 receptor to B7
GB9022545D0 (en) † 1990-10-17 1990-11-28 Wellcome Found Culture medium
US5318898A (en) * 1991-04-02 1994-06-07 Genetics Institute, Inc. Production of recombinant bone-inducing proteins
TW318142B (da) * 1991-06-03 1997-10-21 Mitsubishi Chemicals Co Ltd
US5844095A (en) * 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
KR100238712B1 (ko) * 1991-06-27 2000-01-15 스티븐 비. 데이비스 씨티엘에이4 수용체,그를 함유한 연합단백질 및 그의 용도
US5770197A (en) * 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
US6090914A (en) * 1991-06-27 2000-07-18 Bristol-Myers Squibb Company CTLA4/CD28Ig hybrid fusion proteins and uses thereof
US5851795A (en) * 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5637481A (en) * 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
ATE272708T1 (de) 1992-04-07 2004-08-15 Univ Michigan Immunregulation über die cd28-route
US5773253A (en) 1993-01-22 1998-06-30 Bristol-Myers Squibb Company MYPPPY variants of CTL A4 and uses thereof
US5348877A (en) * 1993-03-12 1994-09-20 Boyce Thompson Institute For Plant Research, Inc. Method of adapting anchorage-dependent cell lines to suspension conditions
AU7107794A (en) 1993-06-10 1995-01-03 Regents Of The University Of Michigan, The Cd28 pathway immunosuppression
SE9303601D0 (sv) * 1993-11-01 1993-11-01 Kabi Pharmacia Ab Improved cell cultivation method and medium
MX9605088A (es) * 1994-04-28 1997-08-30 Boehringer Ingelheim Pharma Metodos para proliferar y diferenciar celulas b y sus usos.
US6719972B1 (en) 1994-06-03 2004-04-13 Repligen Corporation Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
EP0817842A1 (en) * 1995-03-24 1998-01-14 Takeda Chemical Industries, Ltd. Antibody to human betacellulin and use thereof
US5705364A (en) * 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US5721121A (en) * 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US5817290A (en) * 1995-07-28 1998-10-06 Beth Israel Deaconess Medical Center Method of and test kit for mutagenesis testing
JP4306813B2 (ja) * 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
US6750334B1 (en) * 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
US5728580A (en) * 1996-02-20 1998-03-17 Cornell Research Foundation, Inc. Methods and culture media for inducing single cell suspension in insect cell lines
US6043092A (en) * 1996-03-18 2000-03-28 University Of Pittsburgh Cell culture media for mammalian cells
IL125928A (en) * 1996-03-20 2002-11-10 Bristol Myers Squibb Co The use of soluble ligands that react with CTLA4, B7, CD40, gp39 and / or CD28 for the preparation of pharmaceutical preparations
US5856159A (en) * 1996-03-27 1999-01-05 Cytel Corporation Production of galactosyltransferase
US5851800A (en) * 1996-05-14 1998-12-22 Pharmacia & Upjohn Ab Process for producing a protein
EP0953041A4 (en) 1996-08-30 2003-01-29 Life Technologies Inc SERUM-FREE CULTURAL MEDIUM FOR MAMMAL CELLS AND THEIR USE
US20030219863A1 (en) * 1997-01-31 2003-11-27 Bristol-Myers Squibb Company Soluble CTLA4 mutant molecules and uses thereof
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
DK1036179T4 (da) † 1997-12-03 2014-03-31 Roche Diagnostics Gmbh Fremgangsmåde til fremstilling af polypeptider med egnet glycosilering
ATE314485T1 (de) 1998-05-29 2006-01-15 Genentech Inc Zellkulturverfahren für die produktion von glycoproteinen
DE19852729A1 (de) * 1998-11-16 2000-05-18 Werner Reutter Rekombinante Glycoproteine, Verfahren zu ihrer Herstellung, sie enthaltende Arzneimittel und ihre Verwendung
AU773845B2 (en) * 1998-11-18 2004-06-10 Neose Technologies, Inc. Low cost manufacture of oligosaccharides
TR200504220T2 (tr) 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
PT1171615E (pt) 1999-04-26 2007-03-30 Genentech Inc Processo de cultura celular para glicoproteínas
ES2266159T3 (es) 2000-02-08 2007-03-01 Genentech, Inc. Mejora de la galactosilacion de glicoproteinas recombinantes.
AU2001236739A1 (en) 2000-02-08 2001-08-20 Genentech Inc. Improved sialylation of glycoproteins
US7094874B2 (en) * 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
DE60104282T2 (de) 2000-05-26 2005-10-13 Bristol-Myers Squibb Co. Lösliche mutante ctla4 moleküle und deren verwendung
MXPA02012157A (es) * 2000-06-09 2003-06-06 Bristol Myers Squibb Co Metodos para regular una respuesta inmune mediada por celulas al bloquear se°ales linfociticas y al bloquear la adhesion mediada por el antigeno 1 asociado con la funcion de linfocitos.
ATE401909T1 (de) * 2000-07-03 2008-08-15 Bristol Myers Squibb Co Verwendung von löslichen ctla4-mutanten zur behandlung von rheumatoider arthritis
US20040022787A1 (en) * 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
US20020099183A1 (en) * 2000-08-23 2002-07-25 Pluschkell Stefanie Beate Process for the preparation of neutrophil inhibitory factor
HUP0303930A3 (en) * 2001-01-26 2012-09-28 Univ Emory Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
ATE390931T1 (de) * 2001-05-23 2008-04-15 Bristol Myers Squibb Co Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4- mutationsmolekülen
SI1543106T1 (sl) † 2002-07-15 2007-08-31 Immunex Corp Postopki in mediji za nadziranje sialilacije proteinov, ki jih proizvajajo sesalske celice
US6924124B1 (en) * 2002-08-23 2005-08-02 Immunex Corporation Feeding strategies for cell culture
ES2354610T5 (es) * 2002-12-23 2020-09-14 Bristol Myers Squibb Co Mejora de la calidad del producto en procedimientos de cultivo de células de mamífero para la producción de proteína
JP4541157B2 (ja) 2002-12-23 2010-09-08 ブリストル−マイヤーズ スクイブ カンパニー タンパク質を製造するための哺乳類細胞培養法
JP2007501243A (ja) 2003-08-04 2007-01-25 ブリストル−マイヤーズ　スクイブ　カンパニー 可溶性ｃｔｌａ４分子を用いる心臓血管疾患の治療方法
US20070161047A1 (en) * 2006-01-09 2007-07-12 Xiaotian Zhong Methods of labeling transiently expressed proteins in large-scale eukaryotic cell cultures

Also Published As

Publication number Publication date
PL377603A1 (pl) 2006-02-06
ES2354610T5 (es) 2020-09-14
EP1576182B2 (en) 2020-01-15
SI1576182T2 (sl) 2020-07-31
IL168873A (en) 2013-04-30
SI1576182T1 (sl) 2011-01-31
CO5590971A2 (es) 2005-12-30
US20050084933A1 (en) 2005-04-21
CN1820080A (zh) 2006-08-16
TW200504221A (en) 2005-02-01
WO2004058944A2 (en) 2004-07-15
US20080070280A1 (en) 2008-03-20
EP1576182B1 (en) 2010-11-17
EP1576182A2 (en) 2005-09-21
DE60335024D1 (de) 2010-12-30
CN100402660C (zh) 2008-07-16
CY1111358T1 (el) 2015-08-05
CA2508925A1 (en) 2004-07-15
WO2004058944A8 (en) 2005-07-21
CA2508925C (en) 2012-08-28
JP2006511224A (ja) 2006-04-06
US7332303B2 (en) 2008-02-19
BR0316882A (pt) 2005-10-25
DK1576182T3 (da) 2011-02-21
KR20050103466A (ko) 2005-10-31
KR101088223B1 (ko) 2011-11-30
HK1075474A1 (en) 2005-12-16
ES2354610T3 (es) 2011-03-16
PT1576182E (pt) 2011-01-21
JP4496086B2 (ja) 2010-07-07
ATE488600T1 (de) 2010-12-15
MXPA05006522A (es) 2006-02-17
EP1576182A4 (en) 2007-05-02
AU2003303394B2 (en) 2009-02-19
AU2003303394A1 (en) 2004-07-22
WO2004058944A3 (en) 2004-09-10
TWI328614B (en) 2010-08-11

Similar Documents

Publication Publication Date Title
DK1576182T4 (da) Produktkvalitetsforbedring ved fremgangsmåde med dyrkning af pattedyreceller til proteinfremstilling
TW200512297A (en) Mammalian cell culture processes for protein production
DK1623023T3 (da) Kulturer af E1-immortaliserede celler og fremgangsmåder til dyrkning deraf til forögelse af produktudbytter derfra
JP6603628B2 (ja) 改良型細胞培養培地
Ljunggren et al. Catabolic control of hybridoma cells by glucose and glutamine limited fed batch cultures
Pham et al. Transient gene expression in HEK293 cells: peptone addition posttransfection improves recombinant protein synthesis
KR101362805B1 (ko) 개선된 세포 배양 배지
EA201490631A1 (ru) Способы культивирования клеток млекопитающих для получения белка
WO2000056905A3 (en) Method for enhancing and/or improving plant growth and/or yield or modifying plant architecture
UA92157C2 (ru) Способ продуцирования гормона роста
TW200636068A (en) A method of culturing a cell and use of the same
GB2429211A (en) Feeder independent extended culture of embryonic stem cells
DK1238057T3 (da) Fremgangsmåde til produktion af vedhæftende dyreceller
KR19990047907A (ko) 노보바이오신을 첨가한 배지를 사용하여 재조합 단백질의 생산량을 증가시키는 배양방법
BRPI0517942B8 (pt) processo para a produção do hormônio de crescimento humano recombinante (rhgh) e usos de um meio de cultura de células isento de soro
Li et al. Establishment and characterization of the fibroblast line from Silkie Bantam
RU2021127370A (ru) Линия клеток, содержащая новый маркер отбора, и ее применение для продуцирования белков
RU2008100689A (ru) Способ получения белкового гидролизата
UA81564C2 (ru) Способ дифференциации стромальных столбовых клеток человека в культуральной среде in vitro
UY26907A1 (es) Proceso para preparar un factor inhibidor de neutrófilos